- Home
- GLUE vs AMRC Comparison
GLUE vs AMRC Comparison
Compare GLUE & AMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | AMRC |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GLUE | AMRC |
|---|---|---|
| Price | $13.42 | $22.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $32.00 | ★ $37.88 |
| AVG Volume (30 Days) | ★ 1.5M | 801.4K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $123,672,000.00 | ★ $1,769,928,000.00 |
| Revenue This Year | N/A | $10.71 |
| Revenue Next Year | $2.45 | $9.07 |
| P/E Ratio | $72.42 | ★ N/A |
| Revenue Growth | ★ 63.54 | N/A |
| 52 Week Low | $4.68 | $18.38 |
| 52 Week High | $25.77 | $44.93 |
Technical Indicators
Market Signals| Indicator | GLUE | AMRC |
|---|---|---|
| Relative Strength Index (RSI) | 31.76 | 42.37 |
| Support Level | $13.95 | $18.38 |
| Resistance Level | $16.66 | $23.96 |
| Average True Range (ATR) | 0.64 | 1.35 |
| MACD | 0.06 | -0.36 |
| Stochastic Oscillator | 23.36 | 19.29 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About AMRC Ameresco Inc.
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.